Quizartinib; AC-010220; AC-220

Nomen chemicum:

N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl ]phenyl}urea

SMILES Code:

O=C(NC1=CC=C(C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)C=C1)NC6=NOC(C(C)(C)C)=C6

InChi Code:

InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22- 18-35-23-9-8-21(16-24(23)40-28(35)31-22) 38-15-12-34-10-13-37-14-11-34/h4- 9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36);

InChi Key:

CVWXJKQAOSCOAB-UHFFFAOYSA-N

Keyword:

Quizartinib, AC-010220, AC010220, AC 010220, AC-220, AC220, AC 220, 950769-58-1

Solubilitas:Solutum in DMSO

Repono:0 - 4° C pro brevi termino (dies ad hebdomades), vel -20° C ad terminum longum (menses)

Descriptio:

Quizartinib inhibitor est kinasi tyrosinae FMS relatae 3 (FLT3; Kd = 1.6 nM) et selectivam altam demonstrat FLT3 cum probata contra tabulam 227 kinases additas. Inhibet propagationem leukemia cell lineae MV4-11 humanae, quae mutationem homozygoam FLT3-ITD accipit, cum IC50 valore 0.56 nM.1 In 1 mg/kg/die, quizartinib in mure superstitem extendere monstratum est. exemplar of FLT3-ITD myeloidalis acuta leukemia et tumores in musculo xenografi dependens ad 10 mg/kg tumores extirpare.

Target: FLT3